JPWO2021046112A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021046112A5 JPWO2021046112A5 JP2022513850A JP2022513850A JPWO2021046112A5 JP WO2021046112 A5 JPWO2021046112 A5 JP WO2021046112A5 JP 2022513850 A JP2022513850 A JP 2022513850A JP 2022513850 A JP2022513850 A JP 2022513850A JP WO2021046112 A5 JPWO2021046112 A5 JP WO2021046112A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyldiyl
- heterocyclyldiyl
- peg
- aminoquinoline
- alkenyldiyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940127121 immunoconjugate Drugs 0.000 claims description 29
- 239000003814 drug Substances 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 6
- -1 proline amino acid Chemical class 0.000 claims 33
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 150000001413 amino acids Chemical group 0.000 claims 8
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 3
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 3
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 229960000106 biosimilars Drugs 0.000 claims 3
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 125000005647 linker group Chemical group 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- GCMNJUJAKQGROZ-UHFFFAOYSA-N 1,2-Dihydroquinolin-2-imine Chemical group C1=CC=CC2=NC(N)=CC=C21 GCMNJUJAKQGROZ-UHFFFAOYSA-N 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 230000001268 conjugating effect Effects 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 1
- 230000008484 agonism Effects 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 229950002916 avelumab Drugs 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 201000007492 gastroesophageal junction adenocarcinoma Diseases 0.000 claims 1
- 229950000518 labetuzumab Drugs 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 229960002087 pertuzumab Drugs 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 230000007112 pro inflammatory response Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962895379P | 2019-09-03 | 2019-09-03 | |
| US62/895,379 | 2019-09-03 | ||
| PCT/US2020/049041 WO2021046112A1 (en) | 2019-09-03 | 2020-09-02 | Aminoquinoline compounds, immunoconjugates, and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022546110A JP2022546110A (ja) | 2022-11-02 |
| JP2022546110A5 JP2022546110A5 (https=) | 2023-08-30 |
| JPWO2021046112A5 true JPWO2021046112A5 (https=) | 2023-08-30 |
Family
ID=72561946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022513850A Pending JP2022546110A (ja) | 2019-09-03 | 2020-09-02 | アミノキノリン化合物、免疫複合体、及びそれらの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220313835A1 (https=) |
| EP (1) | EP4025254A1 (https=) |
| JP (1) | JP2022546110A (https=) |
| CN (1) | CN114630684A (https=) |
| CA (1) | CA3148694A1 (https=) |
| WO (1) | WO2021046112A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102726248B1 (ko) | 2016-07-07 | 2024-11-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| CN115996756A (zh) * | 2020-05-08 | 2023-04-21 | 博尔特生物治疗药物有限公司 | 弹性蛋白酶底物肽连接子免疫缀合物及其用途 |
| CN118475372A (zh) | 2021-10-29 | 2024-08-09 | 博尔特生物治疗药物有限公司 | 具有半胱氨酸突变抗体的tlr激动剂免疫缀合物及其用途 |
| JP2026500913A (ja) | 2022-12-13 | 2026-01-09 | クリネティックス ファーマシューティカルズ，インク． | ソマトスタチンサブタイプ－２受容体（ｓｓｔ２ｒ）標的化治療薬及びその使用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US723288A (en) | 1901-10-26 | 1903-03-24 | Harry South Lewis | Cipher-key for cryptographic codes. |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5874540A (en) | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| PT1308456E (pt) | 1998-05-06 | 2007-12-03 | Genentech Inc | Purificação de anticorpos por cromatografia de permuta iónica |
| CA2399940A1 (en) | 2000-04-13 | 2001-10-25 | The Rockefeller University | Enhancement of antibody-mediated immune responses |
| BRPI0411514A (pt) * | 2003-06-20 | 2006-08-01 | Coley Pharm Gmbh | antagonistas de receptor toll-like de molécula pequena |
| WO2005086875A2 (en) | 2004-03-11 | 2005-09-22 | City Of Hope | A humanized anti-cea t84.66 antibody and uses thereof |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| WO2006073921A2 (en) | 2004-12-30 | 2006-07-13 | The Rockefeller University | Compositions and methods for enhanced dendritic cell maturation and function |
| US20080286819A1 (en) | 2005-11-07 | 2008-11-20 | Ravetch Jeffrey V | Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof |
| LT1976880T (lt) | 2005-12-21 | 2016-10-10 | Amgen Research (Munich) Gmbh | Farmacinės kompozicijos, pasižyminčios atsparumu tirpiam cea |
| EP2144628B1 (en) | 2007-05-08 | 2012-10-17 | Genentech, Inc. | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
| MX2010003718A (es) | 2007-10-19 | 2010-04-21 | Genentech Inc | Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo. |
| JP5889912B2 (ja) | 2010-11-17 | 2016-03-22 | ジェネンテック， インコーポレイテッド | アラニニルメイタンシノール抗体コンジュゲート |
| RS56793B1 (sr) | 2011-03-02 | 2018-04-30 | Roche Glycart Ag | Cea antitela |
| HUE033369T2 (en) | 2012-11-20 | 2017-11-28 | Sanofi Sa | Anti-ceacam5 antibodies and uses thereof |
| US9676863B2 (en) | 2014-02-10 | 2017-06-13 | Merck Patent Gmbh | Targeted TGFβ inhibitors |
| MY189836A (en) | 2014-11-21 | 2022-03-11 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
| EP3386536A4 (en) * | 2015-12-07 | 2019-07-31 | Opi Vi- IP Holdco LLC | COMPOSITION OF ANTIBODY CONSTRUCT AGONIST CONJUGATES AND METHOD FOR USE THEREOF |
| WO2018140831A2 (en) * | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| WO2019084060A1 (en) * | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
-
2020
- 2020-09-02 CA CA3148694A patent/CA3148694A1/en active Pending
- 2020-09-02 EP EP20775464.9A patent/EP4025254A1/en active Pending
- 2020-09-02 US US17/637,381 patent/US20220313835A1/en not_active Abandoned
- 2020-09-02 WO PCT/US2020/049041 patent/WO2021046112A1/en not_active Ceased
- 2020-09-02 JP JP2022513850A patent/JP2022546110A/ja active Pending
- 2020-09-02 CN CN202080073294.4A patent/CN114630684A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020252294A5 (https=) | ||
| ES2389298T3 (es) | Agentes citotóxicos que presentan un resto de polietilen glicol reactivo, conjugados citotóxicos que comprenden grupos conectores de polietilen glicol y métodos para preparar y usar los mismos | |
| WO2023131219A1 (en) | Conjugates, compositions and methods of use | |
| RU2748992C2 (ru) | Системы доставки для контролируемого высвобождения лекарственного средства | |
| CA3044898A1 (en) | Di-substituted maleic amide linker for antibody-drug conjugating and preparation method and use thereof | |
| US20200297693A1 (en) | Glucose conjugates of triptolide, analogs and uses thereof | |
| BR112020001345A2 (pt) | método inovador para síntese de amanitinas | |
| JPWO2021067242A5 (https=) | ||
| IL273387B1 (en) | Thylanstatin analogs | |
| JPWO2021226440A5 (https=) | ||
| JP2020534300A5 (https=) | ||
| CN112955434A (zh) | 包含喹啉衍生物的药物偶联物 | |
| JPWO2021081407A5 (https=) | ||
| JPWO2021046112A5 (https=) | ||
| JP2023505509A (ja) | ポリエチレングリコール複合薬、ならびにその調製方法およびその使用 | |
| AU2023387509A1 (en) | An anti-tumor compound and use thereof | |
| JPWO2022272039A5 (https=) | ||
| RU2016119491A (ru) | Конъюгаты антитела к efna4 с лекарственным средством | |
| JPWO2021225892A5 (https=) | ||
| JPWO2020190725A5 (https=) | ||
| JPWO2020089687A5 (https=) | ||
| JPWO2022204536A5 (https=) | ||
| CN120957755A (zh) | 多环类药物偶联物及其制备方法和用途 | |
| JPWO2021081402A5 (https=) | ||
| JPWO2022036101A5 (https=) |